Bank of New York Mellon
SABS icon

Bank of New York Mellon’s SAB Biotherapeutics SABS Stock Holding History

Bank of New York Mellon’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$421K Buy
+107,847
New +$401K ﹤0.01% 3827

Other funds holding SABS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
HWM
HB Wealth Management Atlanta, Georgia $17.8B AUM 24.16% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
KAS
Kestra Advisory Services Austin, Texas $31B AUM 28.39% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return

Bank of New York Mellon's SABS Position: Q2 2026 in Review

Bank of New York Mellon opened a new position in SAB Biotherapeutics (SABS) in Q2 2026: 107,847 shares worth $421K. The stake represents ﹤0.01% of the portfolio and ranks #3827 among its holdings.

22 funds tracked by Wall St. Rank hold SABS as of Q2 2026.

  • Bank of New York Mellon held 107,847 shares of SAB Biotherapeutics worth $421K as of Q2 2026.
  • SAB Biotherapeutics was a new Bank of New York Mellon position in Q2 2026.
  • SAB Biotherapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3827 holding.
  • 22 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.